APRICOT-Mamba: Acuity Prediction in Intensive Care Unit (ICU): Development and Validation of a Stability, Transitions, and Life Sustaining Therapies Prediction Model
Authors: Rashidi Parisa , Contreras Miguel , Silva Brandon , Shickel Benjamin , Davidson Andrea , Ozrazgat-Baslanti Tezcan , Ren Yuanfang , Guan Ziyuan , Balch Jeremy , Zhang Jiaqing , Bandyopadhyay Sabyasachi , Loftus Tyler , Khezeli Kia , Nerella Subhash , Bihorac Azra 
Published: August 2024

On average, more than 5 million patients are admitted to intensive care units (ICUs) in the US, with mortality rates ranging from 10 to 29%. The acuity state of patients in the ICU can quickly change from stable to unstable, sometimes leading to life-threatening conditions. Early detection of deteriorating conditions can assist in more timely interventions and improved survival rates. While Artificial Intelligence (AI)-based models show potential for assessing acuity in a more granular and automated manner, they typically use mortality as a proxy of acuity in the ICU. Furthermore, these methods do not determine the acuity state of a patient (i.e., stable or unstable), the transition between acuity states, or the need for life-sustaining therapies. In this study, we propose APRICOT-M (Acuity Prediction in Intensive Care Unit-Mamba), a 1M-parameter state space-based neural network to predict acuity state, transitions, and the need for life-sustaining therapies in real-time among ICU patients. The model integrates ICU data in the preceding four hours (including vital signs, laboratory results, assessment scores, and medications) and patient characteristics (age, sex, race, and comorbidities) to predict the acuity outcomes in the next four hours. Our state space-based model can process sparse and irregularly sampled data without manual imputation, thus reducing the noise in input data and increasing inference speed. The model was trained on data from 107,473 patients (142,062 ICU admissions) from 55 hospitals between 2014-2017 and validated externally on data from 74,901 patients (101,356 ICU admissions) from 143 hospitals. Additionally, it was validated temporally on data from 12,927 patients (15,940 ICU admissions) from one hospital in 2018-2019 and prospectively on data from 215 patients (369 ICU admissions) from one hospital in 2021-2023. Three datasets were used for training and evaluation: the University of Florida Health (UFH) dataset, the electronic ICU Collaborative Research Database (eICU), and the Medical Information Mart for Intensive Care (MIMIC)-IV dataset. APRICOT-M significantly outperforms the baseline acuity assessment, Sequential Organ Failure Assessment (SOFA), for mortality prediction in both external (AUROC 0.95 CI: 0.94-0.95 compared to 0.78 CI: 0.78-0.79) and prospective (AUROC 0.99 CI: 0.97-1.00 compared to 0.80 CI: 0.65-0.92) cohorts, as well as for instability prediction (external AUROC 0.75 CI: 0.74-0.75 compared to 0.51 CI: 0.51-0.51, and prospective AUROC 0.69 CI: 0.64-0.74 compared to 0.53 CI: 0.50-0.57). This tool has the potential to help clinicians make timely interventions by predicting the transition between acuity states and decision-making on life-sustaining within the next four hours in the ICU.